Doxorubicin(Synonyms: Hydroxydaunorubicin)

天然产物醌类Quinones

Doxorubicin (Synonyms: Hydroxydaunorubicin)

Doxorubicin (Hydroxydaunorubicin) 是一种有细胞毒性的蒽环类抗生素,常用作肿瘤化疗剂。Doxorubicin 抑制拓扑异构酶 II (topoisomerase-II),IC50 为 2.67 μM,从而抑制 DNA 复制。Doxorubicin 下调 AMPK 的基础磷酸化以及下游 acetyl-CoA 羧化酶。Doxorubicin 诱导凋亡 (apoptosis) 和自噬 (autophagy)。Doxorubicin 抑制人 DNA 拓扑异构酶 I (topoisomerase I),IC50 为 0.8 μM。

Doxorubicin(Synonyms: Hydroxydaunorubicin)

Doxorubicin Chemical Structure

CAS No. : 23214-92-8

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy[1][2]. Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM[3].

IC50 & Target[1][2][3][7]

Topoisomerase II

2.67 μM (IC50)

Daunorubicins/Doxorubicins

 

Topoisomerase I

0.8 μM (IC50)

HIV-1

 

体外研究
(In Vitro)

Combination of Doxorubicin (Hydroxydaunorubicin) and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin (Hydroxydaunorubicin) and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts[5]. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3[6].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

543.52

Formula

C27H29NO11

CAS 号

23214-92-8

中文名称

阿霉素;多柔比星

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据
In Vivo:
  • 1.

    Doxorubicin (dissolved with distilled water) is incorporated into 0.035% CaCl2 solution[5].

  • 2.

    Doxorubicin (Adriamycin) is prepared in vehicle (PBS)[6].

参考文献
  • [1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.

    [2]. Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.

    [3]. Foglesong PD, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5.

    [4]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33.

    [5]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2.

    [6]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32.

    [7]. Johansson S, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS. 2006;20(15):1911-1915.

Cell Assay
[4]

160 μL of Hela cells suspension (3×104 cell/mL) is dispensed into three 96-well U-bottom microplates and incubated for 24 h at 37°C in a fully humidified atmosphere of 5% CO2. In plate 1, serial dilutions of Doxorubicin (20 μL; final concentration, 0.1-2 μM) and Simvastatin (20 μL; final concentration, 0.25-2 μM) are added to a final volume of 200 μL and incubated for another 72 h. In plates 2 and 3 serial dilutions of each drug (Simvastatin or Doxorubicin, 40 μL) are added. After an incubation period of 24 h, the medium is aspirated and the cells are washed in PBS. Then, serial dilutions of other drug (40 μL) are added and supplemented with culture medium to a final volume of 200 μL, and incubated for 48 h. Doxorubicin and Simvastatin are used individually as positive controls (40 μL in each well), and the cells treated only with solvent are considered as negative controls. To evaluate cell survival, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated for 3 h. Then the media is replaced with 150 μL of DMSO, and complete solubilization of formazan crystals is achieved by repeated pipetting of the solution. Absorbance is then determined at 540 nm by an ELISA plate reader. Each drug concentration is assayed in 4 or 8 wells and repeated 3 times. The cytotoxic/cytostatic effect of Doxorubicin is expressed as the relative viability (% control) and calculated. Percentage of cell survival in the negative control is assumed as 100. Relative viability=(experimental absorbance-background absorbance)/ (absorbance of untreated controls-background absorbance)×100 %[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[5][6]

Mice[5]
Athymic male nude mice (3-4 weeks old) are used. PC3 cells (4×106) are injected subcutaneously into the flanks of mice. Animals bearing tumors are randomly assigned to treatment groups (five or six mice per group) and treatment initated when xenografts reached volumes of about 100 mm3. Tumors are measured using digital calipers and volume calculated using the formula: Volume=Width2×Length×0.52, where width represents the shorter dimension of the tumor. Treatments are administered as indicated using vehicle (PBS containing 0.1% BSA), Doxorubicin (2-8 mg/kg), Apo2L/TRAIL (500 μg/animal), or a combination of 4 mg/kg Doxorubicin followed by 500 μg Apo2L/TRAIL. Doxorubicin is administered systemically whereas Apo2L/TRAIL is given either intra-tumorally or systemically. All treatments are given once. Mice are monitored daily for signs of adverse effects (listlessness and scruffy apparance). Treatments seemed to be well tolerated. The mean±SEM is calculated for each data point. Differences between treatment groups are analyzed by the student t-test. Differences are considered significant when P<0.05.
Rats[6]
Thirty male Sprague-Dawley rats weighing 250 to 300 g are randomly assigned to 1 of 3 experimental groups: Doxorubicin schedule 1 (Doxorubicin 1, n=10), Doxorubicin schedule 2 (Doxorubicin 2, n=10), or Doxorubicin schedule 3 (Doxorubicin 3, n=10). For all Doxorubicin treatment schedules, the cumulative dose of Doxorubicin is 10 mg/kg. Schedule 1 involves a single bolus intraperitoneal injection of Doxorubicin at 10 mg/kg. Schedule 2 involves 10 intraperitoneal injections of Doxorubicin at 1 mg/kg for 10 consecutive days. Schedule 3 involves 5 intraperitoneal injections of Doxorubicin at 2 mg/kg, once each week, for 5 wk. Immediately before the first Doxorubicin treatment and at weekly intervals after beginning Doxorubicin treatment, blood pressure and cardiac function are assessed in all surviving animals as long as there are at least 3 rats per group.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.

    [2]. Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.

    [3]. Foglesong PD, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5.

    [4]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33.

    [5]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2.

    [6]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32.

    [7]. Johansson S, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS. 2006;20(15):1911-1915.

Proscillaridin A

天然产物 糖类和糖苷 Saccharides and Glycosides

Proscillaridin A; 纯度: 99.74%

Proscillaridin A 是强力的拓扑异构酶 I 和 II topoisomerase I/II 抑制剂,抑制拓扑异构酶 I 和 II 的 IC50 值分别为 30 nM 和 100 nM。

Proscillaridin A

Proscillaridin A Chemical Structure

CAS No. : 466-06-8

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥2630 In-stock
5 mg ¥2250 In-stock
10 mg ¥3750 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Proscillaridin A 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Glycoside Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library

生物活性

Proscillaridin A is a potent poison of topoisomerase I/II activity with IC50 values of 30 nM and 100 nM, respectively[1].

IC50 Target[1]

Topoisomerase I

30 nM (IC50)

Topoisomerase II

100 nM (IC50)

体外研究
(In Vitro)

Proscillaridin A (0-160 nM; 48 hours) reveals the antiproliferative response in a time- as well as dose-dependent manner in MCF-7 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

530.65

Formula

C30H42O8

CAS 号

466-06-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 100 mg/mL (188.45 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8845 mL 9.4224 mL 18.8448 mL
5 mM 0.3769 mL 1.8845 mL 3.7690 mL
10 mM 0.1884 mL 0.9422 mL 1.8845 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.71 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Bielawski K, et al. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A.Biol Pharm Bull. 2006 Jul;29(7):1493-7.

PROTEOSTAT® PDI assay kit 蛋白二硫键异构酶检测试剂盒

PROTEOSTAT® PDI assay kit
蛋白二硫键异构酶检测试剂盒

  • 产品特性
  • 相关资料
  • Q&A
  • 参考文献

PROTEOSTAT® PDI assay kitPROTEOSTAT®  PDI assay kit                              蛋白二硫键异构酶检测试剂盒

蛋白二硫键异构酶检测试剂盒

PROTEOSTAT® PDI 检测试剂盒能够以稳定且高通量的方式定量检测PDI酶活性,适用于从化学库中筛选PDI抑制剂,为筛选PDI酶活性调节剂提供了一种简单、均相的检测方法。

本试剂盒在二硫苏糖醇(DTT)存在的条件下,PDI酶催化胰岛素聚集体的形成,随后与发射红色荧光的 PROTEOSTAT® PDI检测染料结合,通过监测胰岛素减少来实现对PDI酶活性的检测。

相对于使用比浊法检测PDI酶活性,基于荧光的检测法有着极大改进的信号检测窗口和检测下限,以及优越的 Z' 因子(>0.8)。检测中板内和板间CV值为3-5%。

本试剂盒中包含人重组PDI酶(EC 5.3.4.1)、杆菌肽(PDI抑制剂)以及监测PDI酶活性变化所需的全部试剂。

◆产品详情


基础信息


别称:蛋白二硫键异构酶(Protein disulfide isomerase)检测试剂盒

应用:荧光检测

储存条件:避光。避免反复冻融。

运输方式:干冰运输

长期储存温度:–80°C

特点:本试剂盒为筛选蛋白二硫键异构酶(PDI)酶活性的调节剂提供了一种简单、均相的检测方法。

UniProt ID:P07237(人)

监管状态:RUO – 仅供研究使用

技术信息/产品说明:Enzo和PROTEOSTAT®是Enzo Life Sciences, Inc. 的商标。

技术信息/产品说明:Enzo的部分产品和产品应用受美国、外国专利及正在申请的专利保护。



品质保证


(1)按照手册中的步骤, PROTEOSTAT® PDI检测试剂盒可用于检测以下样品:

(1)① 含PDI的胰岛素;② 不含PDI的胰岛素;③ 含有PDI和杆菌肽的胰岛素。

(2)Z' 因子高于0.8。

(3)PDI活性至少可被杆菌肽抑制50%。



使用/稳定性


在产品标签注明的日期前,试剂盒组分在适当的储存条件下可稳定保存。

可存放于-20°C的无霜冰箱中,或在–80°C下长期保存。



组分


● PROTEOSTAT® PDI 检测试剂

● PDI(人)(重组)

● 胰岛素(冻干)

● 杆菌肽(抑制剂对照,冻干)

● PBE 缓冲液

● 终止试剂

● DTT(10 mM)

● 去离子水


※ 本页面产品仅供研究用,研究以外不可使用。

参考文献


 1. 

Thioredoxin reductase is a major regulator of metabolism in leukemia cells: S. Karunanithi, et al.; Oncogene 41388 (2021), Abstract;


 2.

Molecular docking‐assisted screening reveals tannic acid as a natural protein disulphide isomerase inhibitor with antiplatelet and antithrombotic activities: L. Ren, et al.; J. Cell. Mol. Med. 24, 14257 (2020), AbstractFull Text

 3.

PDI knockdown inhibits seizure activity in acute seizure and chronic epilepsy rat models via S-nitrosylation-independent thiolation on NMDA receptor: A.R. Jeon, et al.; Front. Cell. Neurosci. 12, 438 (2018), Application(s): Hippocampal tissue lysates, AbstractFull Text

 4.

The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition: S. Hager, et al.; Cell Death Dis. 9, 1052 (2018), AbstractFull Text

 5.

Tissue Factor Coagulant Activity is Regulated by the Plasma Membrane Microenvironment: Y. Yu, et al.; Thromb. Haemost. 118, 990 (2018), Application(s): In-vitro activity assay, Abstract;


 6.

Curcumin and Curcuma longa L. extract ameliorate lipid accumulation through the regulation of the endoplasmic reticulum redox and ER stress: H.Y. Lee, et al.; Sci. Rep. 7, 6513 (2017), Application(s): PDI assay of tissue lysates, AbstractFull Text

 7.

Nox4 regulates the eNOS uncoupling process in aging endothelial cells: H.Y. Lee, et al.; Free Radic. Biol. Med. 113, 26 (2017), Application(s): PDI assay of HUVEC cell lysates, Abstract;


 8.

PDI regulates seizure activity via NMDA receptor redox in rats: J.Y. Kim, et al.; Sci. Rep. 7, 42491 (2017), Application(s): Hippocampal tissue lysates, Abstract; Full Text

 9.

Protein disulfide isomerase regulates renal AT1 receptor function and blood pressure in rats: X. Wang, et al.; Am. J. Physiol. Renal. Physiol. 313, F461 (2017), Application(s): Renal tissue lysates, AbstractFull Text

10.

Requirement of zinc transporter SLC39A7/ZIP7 for dermal development to fine-tune endoplasmic reticulum function by regulating protein disulfide isomerase: B.H. Bin, et al.; J. Invest. Dermatol. 137, 1682 (2017), Application(s): ER fractions from murine osteoblasts, Abstract;


11. 

Succination of protein disulfide isomerase links mitochondrial stress and endoplasmic reticulum stress in the adipocyte during diabetes: A.M. Manuel, et al.; Antioxid. Redox Signal. 27, 1281 (2017), Application(s): 3T3-L1 adipocytes and adipose tissue lysates, AbstractFull Text

12.

Adverse outcomes associated with cigarette smoke radicals related to damage to protein disulfide isomerase: H. Kenche, et al.; J. Biol. Chem. 291, 4763 (2016), Abstract;


13.

Adverse Outcomes Associated with Cigarette Smoke Radicals Related to Damage to Protein-disulfide Isomerase: H. Kenche, et al.; J. Biol. Chem. 291, 4763 (2016), Application(s): in-vitro assay with recombinant PDI, AbstractFull Text

14.

Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity: K. Mätlik, et al.; Cell Death Dis. 6, e2032 (2015), AbstractFull Text

15.

Methods of measuring protein disulfide isomerase activity: a critical overview: M.M. Watanabe, et al.; Front. Chem. 2, 73 (2014), Application(s): Review on available assays to measure PDI activity, AbstractFull Text

16.

N-octanoyl dopamine treatment of endothelial cells induces the unfolded protein response and results in hypometabolism and tolerance to hypothermia: E. Stamellou, et al.; PLoS One 9, e99298 (2014), AbstractFull Text

17.

The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma: G. Tufo, et al.; Cell Death Differ. 21, 685 (2014), Application(s): Evaluation of PDI activity in whole extracts and ER fractions, Abstract;


18.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase: F. Langer, et al.; Blood 121, 2324 (2013), Abstract;


19.

Oxidative processing of latent Fas in the endoplasmic reticulum controls the strength of apoptosis: V. Anathy, et al.; Mol. Cell. Biol. 32, 3464 (2012), Abstract;



◆一般参考文献


 1. 

Attachment and entry of Chlamydia have distinct requirements for host protein disulfide isomerase: S. Abromaitis & R.S. Stephens; PLoS Pathog. 5, e1000357 (2009), Abstract;


 2.

Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of Leishmania chagasi promastigotes by macrophages: C. X. Santos, et al.; J. Leukoc. Biol. 86, 989 (2009), Abstract;


 3.

The proteostasis boundary in misfolding diseases of membrane traffic: D.M. Hutt, et al.; FEBS Lett. 583, 2639 (2009), Abstract;


 4.

Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress: P.E. Lovat, et al.; Cancer Res. 68, 5363 (2008), Abstract;


 5.

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57: M. Corazzari, et al.; Br. J. Cancer 96, 1062 (2007), Abstract;


 6.

Coupling endoplasmic reticulum stress to the cell death program: R.V. Rao, et al.; Cell Death Differ. 11, 372 (2004), Abstract;


 7.

Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion: R. Barbouche, et al.; J. Biol. Chem. 278, 3131 (2003), Abstract;


 8.

Protein disulfide isomerase, a component of the estrogen receptor complex, is associated with Chlamydia trachomatis serovar E attached to human endometrial epithelial cells: C.H. Davis, et al.; Infect. Immun. 70, 3413 (2002), Abstract;


 9.

Protein-disulfide isomerase-mediated reduction of the A subunit of cholera toxin in a human intestinal cell line: P.A. Orlandi; J. Biol. Chem. 272, 4591 (1997), Abstract;


10.

Acceleration of reactivation of reduced bovine pancreatic ribonuclease by a microsomal system from rat liver: R.F. Goldberger, et al.; J. Biol. Chem. 238, 628 (1963), Abstract;


产品列表
产品编号 产品名称 产品规格 产品等级 备注
ENZ-51024-KP002 PROTEOSTAT PDI assay kit 
PROTEOSTAT PDI检测试剂盒
2×96 tests
ENZ-51024-KP050 PROTEOSTAT PDI assay kit 
PROTEOSTAT PDI检测试剂盒
50 tests

PDI monoclonal antibody (1D3) 蛋白质二硫键异构酶单克隆抗体(1D3) 品牌:Enzo


PDI monoclonal antibody (1D3)

蛋白质二硫键异构酶单克隆抗体(1D3)

品牌:Enzo
CAS No.:
储存条件:-20℃
纯度:
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

ENZ-ABS686-0050

50 µg 4,260.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

PDI monoclonal antibody (1D3) 蛋白质二硫键异构酶单克隆抗体(1D3) 品牌:Enzo


PDI monoclonal antibody (1D3)

蛋白质二硫键异构酶单克隆抗体(1D3)

品牌:Enzo
CAS No.:
储存条件:-20℃
纯度:
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

ENZ-ABS686-0200

200 µg 9,310.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

PDI monoclonal antibody (1D3) (PE conjugate) 蛋白质二硫键异构酶单克隆抗体(1D3)(PE标记) 品牌:Enzo


PDI monoclonal antibody (1D3) (PE conjugate)

蛋白质二硫键异构酶单克隆抗体(1D3)(PE标记)

品牌:Enzo
CAS No.:
储存条件:+4℃
纯度:
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

ENZ-ABS686PE-0050

50 µg 8,820.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。